Phase I clinical study of the drug candidate IRL757 in healthy adults aged 65 and older
Latest Information Update: 06 Feb 2025
At a glance
- Drugs IRL-757 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions
Most Recent Events
- 31 Jan 2025 Status changed from recruiting to completed.
- 31 Jan 2025 Results presented in the IRLAB Media Release.
- 17 Oct 2024 New trial record